Skip to main content

Health condition · Clinically reviewed

MOGAD, the antibody disease that mimics - but isn’t - MS.

A distinct inflammatory condition of the brain, spinal cord and optic nerves, with its own antibody, its own imaging pattern and its own treatment path.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against emerging international MOGAD diagnostic criteria and specialist neurology guidance, with sources listed at the end.

  • 03

    Current for 2026

    Reflects the latest thinking on cell-based antibody testing, acute treatment and long-term relapse prevention.

Key facts

MOGAD at a glance.

The essentials, in plain English - what it is, who it affects, and how it’s diagnosed and treated today.

  • What it is

    An autoimmune inflammatory condition of the brain, spinal cord and optic nerves, driven by antibodies against myelin oligodendrocyte glycoprotein (MOG).

  • Distinct from MS

    A separate disease from multiple sclerosis and NMOSD, with its own antibody, imaging pattern and treatment approach.

  • Who it affects

    Both children and adults - presentation differs by age, with ADEM more typical in children and optic neuritis more typical in adults.

  • Key test

    A cell-based assay for MOG antibodies, run at a specialist commissioned neuroimmunology laboratory.

  • Acute treatment

    High-dose intravenous corticosteroids first-line, with plasma exchange or IVIg for severe or steroid-resistant attacks.

  • Course

    Can be monophasic (one attack, no recurrence) or relapsing - ongoing monitoring is needed to work out which.

Why this guide matters

A distinct disease, a distinct plan.

MOGAD has only recently been separated out from MS and NMOSD. Getting the diagnosis right changes the treatment and the outlook. The three points below shape everything else on this page.

  • The antibody test is the key

    A cell-based assay for MOG antibodies is what separates MOGAD from MS and NMOSD - more specific than older test methods.

  • Course varies person to person

    Some people have a single attack and never relapse; others need long-term relapse prevention - ongoing monitoring tells you which.

  • Early, aggressive treatment helps

    High-dose steroids, and escalation to plasma exchange or IVIg when needed, gives the best chance of visual and functional recovery.

How the diagnosis is made

From first attack to a confirmed diagnosis.

The steps a specialist neurology or neuroimmunology team will normally follow, in order - so you know what to expect and why.

  1. 01

    Assessing

    Clinical presentation review

    A detailed history of visual loss, limb weakness, sensory change or encephalopathy, and how it evolved.

  2. 02

    Assessing

    MOG antibody testing

    A cell-based assay - the key diagnostic test, more specific than older techniques - sent to a specialist commissioned neuroimmunology laboratory.

  3. 03

    Confirming

    MRI brain and spine

    Identifies characteristic lesion patterns, often different from typical MS lesions, and maps the extent of demyelination - specialist neuroradiology.

  4. 04

    Confirming

    Lumbar puncture and CSF analysis

    Assesses inflammation and oligoclonal bands, typically negative or a different pattern to MS - an important distinguishing feature.

  5. 05

    Confirming

    Visual evoked potentials and OCT

    Assess optic nerve involvement and track recovery after optic neuritis - specialist neuro-ophthalmology.

  6. 06

    Preparing

    Differentiation from MS and NMOSD

    Antibody status, MRI pattern and clinical features together separate MOGAD from other demyelinating diseases - critical given different treatments and outlook.

  7. 07

    Preparing

    Specialist MDT review

    A specialist commissioned neurology and neuroimmunology centre confirms the diagnosis and agrees a monitoring and treatment plan.

Typical timeline: assessment to a confirmed diagnosis usually within a few weeks of specialist referral.

Symptoms

What a MOGAD attack looks like.

Optic neuritis and myelitis are the most familiar presentations, but the pattern differs between children and adults. And the features that mean it’s time to escalate.

  • Optic neuritis

    A very common presenting feature - often bilateral and more severe than typical MS-associated optic neuritis, though visual recovery is usually better.

  • Visual loss and eye pain

    Blurred or lost vision with pain on eye movement, sometimes affecting both eyes at once.

  • Transverse myelitis

    Spinal cord inflammation causing limb weakness, sensory disturbance and bladder or bowel dysfunction.

  • ADEM (children)

    Acute disseminated encephalomyelitis - encephalopathy alongside multifocal neurological symptoms, more common as a first presentation in children.

  • Brainstem syndromes

    Selective brainstem involvement can cause double vision, vertigo, swallowing difficulty or facial weakness.

  • Relapsing course

    Relapses are common over time, though a single monophasic episode - particularly in children - also occurs.

  • Age-related pattern

    Children more often present with ADEM-like illness; adults more often present with optic neuritis or myelitis.

  • Red flag - rapid deterioration

    Fast-progressing weakness, encephalopathy or bilateral visual loss needs urgent same-day neurology assessment.

Treatment

How MOGAD is treated.

High-dose steroids for acute attacks, escalation when needed, and individualised long-term relapse prevention for those with a relapsing course.

  • IV methylprednisolone

    High-dose intravenous corticosteroids - first-line treatment for acute relapses or attacks, given under specialist commissioned neurology care.

  • Plasma exchange

    Used for severe attacks that do not respond adequately to steroids, particularly severe optic neuritis or myelitis.

  • Intravenous immunoglobulin

    An alternative or adjunct for acute attacks, particularly favoured in children - specialist commissioned.

  • Rituximab

    Anti-CD20 B-cell depletion therapy used for long-term relapse prevention in patients with a relapsing course.

  • Azathioprine or mycophenolate

    Steroid-sparing immunosuppressants used for long-term prevention, chosen based on individual tolerance and response.

  • Low-dose oral corticosteroids

    An option for some patients requiring ongoing relapse prevention, individualised to the person.

  • Emerging targeted therapies

    Complement inhibitors and other biologics are an active area of research, accessed via specialist centres or clinical trials.

  • Rehabilitation and vision support

    Physiotherapy, occupational therapy and low-vision or neuro-ophthalmology services for those with lasting motor or visual impairment.

What this guide is based on

The sources behind every claim on this page.

Emerging international diagnostic criteria and specialist neurology guidance, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your neurologist knows your history and imaging and can tell you which parts apply to you. If in doubt, get seen.

  • International MOGAD Panel. Proposed diagnostic criteria for MOGAD.

  • Association of British Neurologists. Guidance on demyelinating disease and neuroimmunology referral pathways.

  • NHS England. Specialist commissioning for neuroimmunology services.

  • Peer-reviewed neurology literature on MOG-antibody disease, acute treatment and relapse prevention.

Red flags

When MOGAD needs urgent attention.

Most follow-up happens in specialist clinics. These are the situations that can’t wait for a routine appointment.

  • Sudden bilateral visual loss

    Rapid loss of vision in both eyes needs same-day ophthalmology and neurology assessment.

  • Rapidly progressive limb weakness

    Fast-evolving weakness or numbness suggesting myelitis is a neurological emergency.

  • Encephalopathy

    Confusion, altered consciousness or behavioural change alongside neurological signs, especially in children, needs urgent assessment for ADEM.

  • Bladder or bowel dysfunction

    New urinary retention or incontinence with limb symptoms points to spinal cord involvement and needs urgent review.

  • Breathing or swallowing difficulty

    Brainstem involvement affecting breathing or swallowing is a medical emergency requiring immediate hospital care.

  • Steroid attack not responding

    An attack failing to improve on high-dose steroids should prompt early escalation to plasma exchange or IVIg.

  • Suspected relapse

    New or recurring neurological symptoms after a previous attack should be assessed promptly rather than waiting.

  • Misdiagnosis as MS

    Because MOGAD mimics MS, a mismatch between clinical course and treatment response should prompt MOG-antibody testing.

  • Pregnancy planning

    Women with MOGAD considering pregnancy should discuss immunosuppressant choice and relapse risk with their specialist team beforehand.

Living with it

A manageable condition, with the right team behind you.

Four things that make the biggest difference day to day - watching for new symptoms, keeping follow-up appointments, and using vision and rehabilitation support when you need it.

A quiet reminder

Most people recover well from a MOGAD attack.

Visual and functional recovery is often better than in comparable MS attacks - early, well-managed treatment gives you the best chance.

  1. 01 Monitor

    Track new symptoms early

    Note any new visual, sensory or motor change and contact your team promptly rather than waiting to see if it settles.

  2. 02 Attend

    Keep review appointments

    Regular neurology follow-up helps determine whether your course is monophasic or relapsing, which shapes long-term treatment.

  3. 03 Vision

    Use visual rehabilitation if needed

    Low-vision services and neuro-ophthalmology support can make a real difference after significant optic neuritis.

  4. 04 Support

    Rehabilitation after myelitis

    Physiotherapy and occupational therapy help rebuild strength and function following spinal cord attacks.

Frequently asked

Everything we get asked about MOGAD.

Quick answers on diagnosis, antibody testing, treatment and long-term outlook.

  • What is MOGAD?

    MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease) is a relatively recently characterised autoimmune inflammatory condition of the central nervous system. It is caused by antibodies against MOG and is distinct from multiple sclerosis and neuromyelitis optica spectrum disorder (NMOSD).

  • How is MOGAD different from MS?

    MOGAD has a different antibody, a different typical MRI pattern, and cerebrospinal fluid that is usually negative for the oligoclonal bands often seen in MS. Treatment approaches and prognosis also differ, so accurate testing matters.

  • What is the main test for MOGAD?

    A cell-based assay for MOG antibodies is the key diagnostic test, carried out at a specialist commissioned neuroimmunology laboratory. It is more specific than older antibody testing methods.

  • Does MOGAD affect children differently to adults?

    Yes. Children more often present with acute disseminated encephalomyelitis (ADEM), causing encephalopathy alongside other neurological symptoms, while adults more commonly present with optic neuritis or transverse myelitis.

  • Is MOGAD a one-off illness or does it come back?

    Both patterns happen. Some people have a single monophasic episode, particularly children, while others go on to have a relapsing course. Ongoing specialist monitoring is needed to work out which applies to you.

  • How is a MOGAD attack treated?

    High-dose intravenous corticosteroids are first-line for acute attacks. Plasma exchange or intravenous immunoglobulin are used for severe attacks or when steroids are not enough, particularly for severe optic neuritis or myelitis.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.